Streamlining Prior Authorizations for Oncology with MCG Criteria

Navigating prior authorizations for complex cancer treatments requires precision. Klivira streamlines the application of oncology MCG criteria to accelerate patient access to vital care.

Oncology prior authorization workflows are among the most intricate in healthcare, driven by high-cost biologics, frequent regimen changes, and the urgency of cancer care. Aligning submissions with payer-specific medical necessity guidelines, including those derived from MCG criteria, is critical for minimizing denials and ensuring timely treatment initiation.

The Challenge of Oncology Prior Authorization

Oncology prior authorizations are uniquely complex due to high-cost biologics, frequent regimen changes, and the urgency of cancer care. Treatments involving chemotherapy regimens, biologics and immuno-oncology, radiation therapy, PET imaging, and specialty oral oncolytics frequently trigger PA events, each requiring detailed medical necessity review often guided by criteria like MCG Health's evidence-based guidelines.

Applying MCG Criteria in Oncology Workflows

MCG Health provides evidence-based care guidelines widely adopted by payers for medical necessity determinations. In oncology, these criteria are applied to assess the appropriateness of high-cost treatments, advanced diagnostics, and supportive care. Klivira's platform integrates these criteria to streamline the submission process, ensuring that oncology PA requests align with payer expectations from the outset.

Key Oncology PA Triggers Requiring MCG Alignment

J-code chemotherapy and biologic infusions: Each cycle and regimen change often requires re-authorization against current guidelines.
Advanced imaging (PET/CT, MRI): Staging and surveillance imaging for cancer must meet medical necessity criteria.
Radiation oncology procedures: Treatment plans and specific modalities (IMRT, SBRT) are subject to detailed review.
Genetic and molecular testing: Tumor profiling for treatment selection requires clear clinical rationale.
Specialty oral oncolytics: Oral agents frequently require pharmacy benefit PA, often guided by similar medical necessity criteria.
Supportive care medications: Growth factors and antiemetics, though ancillary, also trigger PA based on criteria.

Documentation Demands for Oncology MCG Criteria

Successful oncology prior authorizations, particularly when reviewed against MCG criteria, hinge on comprehensive clinical documentation. Payers commonly require pathology reports with staging, molecular markers (e.g., ER/PR/HER2, EGFR/ALK/PD-L1), prior treatment history, and performance status (ECOG/Karnofsky). For off-label uses, robust compendium support, such as NCCN Compendium citations, is essential to meet medical necessity standards.

Klivira's Automation for Oncology and MCG Criteria

Criteria-Aware Logic: Surfaces required documentation based on NCCN guidelines and payer-specific medical necessity criteria, including those informed by MCG, at the point of order entry.
Regimen-Level PA Management: Bundles related oncology components (chemo, targeted therapy, immunotherapy) for unified submissions, adapting to payer-specific criteria.
Benefit-Specific Routing: Automatically directs medical benefit PAs (X12 278) and pharmacy benefit PAs (ePA partners) to the correct channel, each adhering to its respective criteria.
Concurrent PA Tracking: Manages the dozens of PA events per patient, from initial diagnosis to surveillance imaging, ensuring all meet criteria.
Denial Prevention Insights: Identifies potential alignment issues with criteria (e.g., step therapy, off-label use without support) before submission, reducing denials.

Accelerating Oncology Care with Criteria Alignment

Misalignment with medical necessity criteria, including MCG guidelines, is a leading cause of oncology PA denials, leading to critical treatment delays. By automating the evidence gathering and submission process, Klivira helps prevent common issues like documentation gaps, off-label use without compendium support, or step therapy conflicts. This proactive approach ensures oncology patients receive timely access to life-saving treatments, improving both clinical outcomes and revenue cycle efficiency.

Frequently asked questions

How does Klivira handle the distinction between medical and pharmacy benefit PAs for oncology drugs, especially when payers apply MCG criteria?

Klivira intelligently routes medical benefit PAs for IV chemotherapy and biologics via X12 278 or payer portals, and pharmacy benefit PAs for oral oncolytics through PBMs and ePA partners. This ensures each submission adheres to the appropriate channel and the specific medical necessity criteria, including MCG, applicable to that benefit type.

What specific documentation does Klivira help gather to meet oncology MCG criteria requirements?

Klivira's platform guides users to collect critical oncology documentation required for MCG criteria review, such as pathology reports with histology, tumor staging, molecular marker results (e.g., EGFR, PD-L1), prior treatment history, performance status (ECOG/Karnofsky), and rationale for regimen changes, directly supporting medical necessity.

How does Klivira address the "regimen-level PA" complexity common in oncology when aligning with MCG criteria?

Klivira supports comprehensive regimen-level PA workflows, bundling related components like chemotherapy, targeted therapy, and immunotherapy into unified submissions where payers accept them. This ensures all elements of a complex oncology regimen are reviewed against applicable medical necessity criteria, including MCG, for efficient approval.

Can Klivira help reduce denials related to "off-label use" or "step therapy" when payers apply MCG criteria in oncology?

Yes, Klivira's criteria-aware logic, informed by NCCN guidelines, helps identify potential issues like off-label use without adequate compendium support or step therapy requirements *before* submission. This proactive flagging enables clinics to gather necessary evidence or adjust the request to align with payer-specific MCG criteria, reducing denials.

How does Klivira assist with the high volume of supportive care PAs in oncology, which also fall under medical necessity criteria?

Klivira tracks and manages concurrent PAs for essential supportive care medications (e.g., G-CSF, antiemetics) alongside primary treatment regimens. This ensures these separate but critical authorizations are processed efficiently, with each submission adhering to the relevant medical necessity criteria, including those informed by MCG.